

Passion for Innovation.
Compassion for Patients.™



Top Management Presentation

Financial Results for FY2016 Q3 (April 1 - December 31, 2016)

DAIICHI SANKYO CO., LTD

George Nakayama
President and CEO

January 31, 2017

Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo's future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo's outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantee that these compounds will become commercially available in indications under investigation.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information

- ◆ **FY2016 Q3 Financial Results**
- ◆ **FY2016 Revised Consolidated Forecast**
- ◆ **Management Updates**
 - **Grow Edoxaban**
 - **Maximize Sales Potential of Injectafer**
- ◆ **R&D Updates**
 - **Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma**
 - **ADC Franchise Enhancement**

FY2016 Q3 Financial Results


Overview of FY2016 Q3 Results

(JPY Bn)

	FY2015 Q3 YTD Results	FY2016 Q3 YTD Results	YoY	
Revenue	758.6	734.4	-3.2% -24.2	
Cost of Sales	237.7	241.7	+4.0	
SG&A Expenses	232.3	220.5	-11.8	
R&D Expenses	138.1	143.5	+5.4	
Operating Profit	150.4	128.7	-14.4% -21.7	
Profit before Tax	145.4	132.4	-13.0	
Profit attributable to owners of the Company	110.7	88.2	-20.4% -22.5	
Currency Rate	USD/JPY	121.70	106.68	-15.02
	EUR/JPY	134.37	118.09	-16.28

Revenue

Decreased by 24.2 Bn JPY (Increased by 16.6 Bn JPY excl. forex impact)




* Increase 4.4 Bn JPY excluding negative impact of 7.0 Bn JPY in Venezuela

**Forex impact USD: -25.8, EUR: -7.6, ASCA: -7.5

Operating Profit

Decreased by 21.7 Bn JPY
(Increased by 1.8 Bn JPY excl. forex impact and special items)



Positive Factors Negative Factors

Special Items


(JPY Bn)

	FY2015 Q3 YTD Results		FY2016 Q3 YTD Results		YoY
Cost of Sales	Gain on sales of subsidiary	-2.4		-	+3.5
	Gain on sales of fixed assets	-1.1			
SG&A Expenses	Restructuring costs in US	6.1	Restructuring costs	10.6	+12.7
	Gain on sales of fixed assets	-8.2			
R&D Expenses	Restructuring costs in R&D	0.3		-	-0.3
Total		-5.3		10.6	+15.9

- : Cost decrease items

Profit Attributable to Owners of the Company

Decreased by 22.5 Bn JPY



*Excl. increase and decrease of share of profit or loss of investments accounted for using the equity method and non-controlling interests

Major Business Units

(JPY Bn)

	FY2015 Q3 YTD Results	FY2016 Q3 YTD Results	YoY	vs. Forecast* (%)
Japan	377.5	390.2	+12.8	77.3%
Daiichi Sankyo Healthcare	39.9	51.9	+12.0	78.6%
Daiichi Sankyo Inc.	145.5	115.8	-29.7	80.4%
Olmesartan	88.4	60.9	-27.5	84.6%
Welchol	37.7	32.2	-5.5	78.5%
Effient	16.4	16.5	+0.1	-
Savaysa	0.3	1.4	+1.1	70.4%
Movantik	1.3	2.9	+1.6	-
Luitpold	69.0	64.3	-4.8	73.0%
Venofer	24.4	21.2	-3.1	75.9%
Injectafer	12.9	17.2	+4.3	71.7%
Daiichi Sankyo Europe	58.1	54.4	-3.7	77.7%
Olmesartan	44.4	34.6	-9.7	82.5%
Efient	3.3	6.1	+2.8	-
Lixiana	0.7	6.1	+5.5	68.2%
Asia, South and Central America (ASCA)	62.6	52.5	-10.1	73.9%

* Calculated based on new forecast updated in Jan.

Major Products in Japan

(JPY Bn)



		FY2015 Q3 YTD Results	FY2016 Q3 YTD Results	YoY	vs. Forecast* (%)
Nexium	ulcer treatment	62.0	67.4	+5.5	81.2%
Olmotec	antihypertensive agent	60.5	54.1	-6.4	78.4%
Memary	Alzheimer's disease treatment	32.7	36.3	+3.7	74.2%
Loxonin	anti-inflammatory analgesic	38.2	29.3	-8.9	79.2%
Tenelia	type 2 diabetes mellitus inhibitor	11.9	19.7	+7.8	75.7%
Lixiana	anticoagulant agent	9.6	17.9	+8.3	71.6%
Rezaltas	antihypertensive agent	14.1	13.6	-0.5	75.6%
Pralia	treatment for osteoporosis	9.0	13.3	+4.3	78.1%
Ranmark	treatment for bone complications caused by bone metastases from tumors	9.4	10.6	+1.3	81.6%
Inavir	anti-influenza treatment	2.5	7.9	+5.4	56.5%
Cravit	synthetic antibacterial agent	14.6	12.0	-2.6	85.8%
Omnipaque	contrast medium	13.2	11.1	-2.1	85.5%
Urief	treatment for dysuria	9.0	8.9	-0.2	80.8%
Artist	treatment for hypertension, angina pectoris and chronic heart failure	12.1	8.5	-3.6	77.3%
Mevalotin	antihyperlipidemic agent	10.8	8.3	-2.5	82.8%
Efient	antiplatelet agent	3.3	7.8	+4.6	71.2%

* Calculated based on new forecast updated in Jan.

FY2016 Revised Consolidated Forecast

FY2016 Revised Consolidated Forecast

(JPY Bn)

	FY2016 Forecast (as of Oct.)	FY2016 Forecast (as of Jan.)	vs. Forecast (as of Oct.)
Revenue	920.0	950.0	+30.0
Cost of Sales	307.0	318.0	+11.0
SG&A Expenses	313.0	315.0	+2.0
R&D Expenses	200.0	207.0	+7.0
Operating Profit	100.0	110.0	+10.0
Profit before Tax	100.0	110.0	+10.0
Profit attributable to owners of the Company	65.0	70.0	+5.0

Major factors
 -Forex impact +13.0
 -Japan +6.0
 -Overseas +9.0

Major factors
 -Forex impact +3.0
 -Increase by increase in revenue +8.0


Major factors
 -Forex impact +5.0
 -Efficient execution of expenses -3.0

Major factors
 -Forex impact +4.0
 -Acceleration of RD +3.0

Currency Rate	USD/JPY	102.67	107.51
	EUR/JPY	114.11	118.57


Assumption of currency rate for Q4
 USD/JPY : 110, EUR/JPY : 120

Grow Edoxaban




Edoxaban: Japan

The DOAC market in Japan is expanding steadily.
The sales market share of Lixiana has reached 14.3% (CY base).




Edoxaban: Japan

As of Nov. 2016, Lixiana gained the 2nd market share in new patients for AF+VTE.



Edoxaban: Germany and South Korea


Steady uptake of sales share after launch



Maximize Sales Potential of Injectafer

Untapped Potential of Injectafer


Injectafer* has grown steadily in the US IV Iron market. However there is still potential for further growth.



*Injectafer is not indicated for patients who are dialysis dependent . Copyright © 2017 QuintilesIMS. Reprinted with permission
Source: IMS National Sales Perspectives Nov. 2016 (includes all US IV Iron sales in all channels including dialysis chains)

Former Design


In IDA* treatment, market beyond Oncologist and Hem/Onc. has not been tapped since LPI focused its limited resources on the area of Oncologist and Hem/Onc.



*IDA: Iron deficiency anemia

New Design as of Jan. 2017

LPI sales team for Injectafer has become DSI employees. DSI/LPI formed a united sales team for Injectafer to accelerate growth.



United sales team for Injectafer

To accelerate growth beyond oncologist and hem/onc

- ◆ Leverage DSI's existing sales & marketing infrastructure for Injectafer
- ◆ Establish a foundation for DSI's oncology business leveraging LPI sales team's experience with oncologists and hem/onc.

Maximize Daiichi Sankyo Group's US business

Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma

Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma

◆ Kite Pharma, Inc. (Kite)

- Located in California, US, Established in 2009, NASDAQ IPO in 2014
- One of the leading development companies for engineered T-cell* therapy in oncology
 - * Chimera Antigen Receptor T-cell: CAR-T
 - T-cell Receptor T-cell: TCR-T
- Strong relationship with key academic research organizations such as the National Cancer Institute of US and venture companies

◆ Scope of the collaboration

➤ Products

✓ **KTE-C19 (CD19 Chimera Antigen Receptor T cell)**

Exclusive license for clinical development, manufacturing and commercialization in Japan. Technology transfer to DS to take advantage of Kite's advanced T cell manufacturing technology

✓ **Kite's lead product candidate will be submitted for review in the United States and is currently in clinical development for future indications**


Optional licensing right for additional products over the next three years

➤ Territory : Japan

◆ Advantage of collaboration



- To enrich innovative oncology pipeline
- To take opportunity to enhance research and development capabilities and build up business infrastructure for the engineered T-cell therapy

Chimera Antigen Receptor T-cell: CAR-T



Production timeline of engineered T-cell

Employing refined and optimized process, therapeutic T-cell is available within 16-18 days with high probability of production success (97%)



* A medical technology in which the blood of a person is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation.

◆ Development Status

Several clinical studies including non-Hodgkin's lymphoma are on-going

- US: **Breakthrough Therapy Designation** (DLBCL¹/TFL²/PMBCL³)
Rolling BLA submission for refractory aggressive non-Hodgkin lymphoma **was initiated in Dec 2016 and will be completed in CY2017 Q1**
- EU : **PRIME** (PRiority MEdicines) Designation (DLBCL)

1. Diffuse large B-cell lymphoma
2. Transformed follicular lymphoma
3. Primary mediastinal B-cell lymphoma

- ✓ Anticipate high probability of development success
- ✓ Potential to be a First-in-Class CAR-T product

(Reference) Major companies having CD19 CAR-T pipeline in clinic
(Source : company web site)


US/EU: Novartis phase 2
Juno/Celgene phase 2
Japan: Novartis phase 2
TAKARA-bio phase 1/2 IND submission

- ◆ Chemorefractory patients with DLBCL, TFL, PMBCL
 - ◆ 76 % of patients with DLBCL achieved objective response ($p < 0.0001$) and 47 % complete remissions (CR) at pre-specified interim analysis
 - ◆ Adverse events in patients with a minimum one month follow up
 - Grade ≥ 3 Cytokine Release Syndrome 13%
 - Grade ≥ 3 Neurologic Events 29%
- } Generally reversible

Best Overall Response in patients with ≥ 3 month follow-up			
Subgroup	N	ORR*	CR
DLBCL	51	76%	47%
TFL/PMBCL	11	91%	73%
Total	62	79%	52%

ADC franchise enhancement

ADC franchise enhancement: U3-1402 HER3-ADC



Desirable characterization for ADC

U3-1402 HER3-ADC


ADC franchise enhancement: U3-1402 HER3-ADC

- HER3 overexpression is reported in breast cancer (BC) and correlated with poor prognosis***
→ Unmet Medical Needs for BC with HER3 overexpression
- Potential anti-tumor activity in non-clinical study**
 - U3-1402 showed tumor regression in BC xenograft models including hormone receptor positive and triple negative breast cancer which does not express HER2. (Right figures)

Patient-derived HER3-positive (HER2-negative) Xenograft models

- HR+ BC model -

- TNBC model -



* Ann Surg. 2010 Jun;251(6):1107-16).

◆ Initiated Phase 1/2 study in Japan

- Research participants
 - ✓ HER3-positive advanced/unresectable metastatic breast cancer, treated with standard treatment, or no standard treatment is available
- Study design (estimated enrollment: 80)
 - ✓ Dose escalation part: safety, tolerability, determination of maximum tolerated dose
 - ✓ Dose finding part: safety efficacy, determination of recommended dose for next phase
 - ✓ Phase 2 part: safety and efficacy at the recommended dose
- Location : Japan (US, in preparation)
- Top Line Results : FY2018 Q4 anticipated

◆ NSCLC with EGFR mutation

- Clinical study for second- or third-line treatment of is in preparation possibly to start in FY2017 Q1

Major R&D milestone events

Project	Indication/Study	Event	Target
CL-108	Pain/Opioid-induced nausea and vomiting (US)	Approval	PDUFA date Jan. 31, 2017
Denosumab	Rheumatoid arthritis (JP)	Approval	FY2017
CHS-0214 (etanercept BS)	Rheumatoid arthritis (JP)	NDA	FY2016
Tivantinib	METIV·HCC Hepatocellular carcinoma Phase 3 study (US/EU)	TLR	CY2017 H1
Mirogabalin	Fibromyalgia Phase 3 study (US/EU)	TLR	CY2017 H1
Quizartinib	QuANTUM-R AML 2nd line treatment Phase 3 study (US/EU/Asia)	DMC interim analysis	CY2017 H1
Pexidartinib	Tenosynovial giant cell tumor (US/EU)	TLR	CY2017 H1
DS-8500	Type 2 Diabetes Phase 2b study (JP) (US)	TLR	FY2016 Q4 FY2017 H1

Red: new information

*TLR: Top Line Results

Reference

Major R&D Pipeline

As of January 2017



Therapeutic area	Phase 1	Phase 2	Phase 3	Application
Oncology	<ul style="list-style-type: none"> ■ DS-3032 (US/JP) (MDM2 inhibitor) ■ PLX7486 (US) (FMS / TRK inhibitor) ■ PLX8394 (US) (BRAF inhibitor) ■ DS-6051 (US/JP) (NTRK/ROS1 inhibitor) ■ PLX9486 (US) (KIT inhibitor) ■ DS-3201 (JP) (EZH1/2 inhibitor) ■ PLX73086 (US) (CSF-1R inhibitor) ■ PLX51107 (US) (BRD4 inhibitor) ■ DS-8895 (JP) (Anti-EPHA2 antibody) ■ DS-8273 (US) (Anti-DR5 antibody) ■ DS-5573 (JP) (Anti-B7-H3 antibody) ■ DS-8201 (JP/US) (Anti-HER2 ADC) ■ U3-1784 (EU) (Anti-FGFR4 antibody) ■ DS-1123 (JP) (Anti-FGFR2 antibody) ■ U3-1402 (JP) (Anti-HER3 ADC) 	<ul style="list-style-type: none"> ■ Patritumab (EU) (U3-1287 / Anti-HER3 antibody) ■ Pexidartinib (US) (PLX3397 / CSF-1R/KIT/FLT3-ITD inhibitor) ■ DS-1647 (JP) (Glioblastoma / G47A virus) 	<ul style="list-style-type: none"> ■ Tivantinib (US/EU) (ARQ 197 / HCC / MET inhibitor) ■ Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody) ■ Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody) ■ Vemurafenib (US/EU) (PLX4032 / Melanoma Adjuvant / BRAF inhibitor) ■ Quizartinib (US/EU/Asia) (AC220 / AML-2nd / FLT3-ITD inhibitor) ■ Quizartinib (US/EU/Asia) (AC220 / AML-1st / FLT3-ITD inhibitor) ■ Pexidartinib (US/EU) (PLX3397 / TGCT / CSF-1R/KIT/FLT3-ITD inhibitor) 	
Cardiovascular-Metabolics	<ul style="list-style-type: none"> ■ DS-1040 (Acute ischemic stroke / TAF1a inhibitor) ■ DS-2330 (Hyperphosphatemia) ■ DS-9231/TS23 (Thrombosis / α2-PI inactivating antibody) ■ DS-9001 (Dyslipidemia / Anti-PCSK9 Anticalin-Albumod) 	<ul style="list-style-type: none"> ■ Esaxerenone (JP) (CS-3150 / DM nephropathy / MR antagonist) ■ DS-8500 (JP/US) (Diabetes / GPR119 agonist) 	<ul style="list-style-type: none"> ■ Edoxaban (JP) (DU-176b / AF / FXa inhibitor) ■ Prasugrel (JP) (CS-747 / Ischemic stroke / Anti-platelet agent) ■ Esaxerenone (JP) (CS-3150 / Hypertension / MR antagonist) 	<ul style="list-style-type: none"> ■ Edoxaban (ASCA etc.) (DU-176b / AF / FXa inhibitor) ■ Edoxaban (ASCA etc.) (DU-176b / VTE / FXa inhibitor)
Others	<ul style="list-style-type: none"> ■ DS-1971 (Chronic pain) ■ DS-1501 (Osteoporosis / Anti-Siglec-15 antibody) ■ DS-7080 (US) (AMD / Angiogenesis inhibitor) ■ DS-2969 (<i>Clostridium difficile</i> infection / GyrB inhibitor) ■ DS-5141 (JP) (DMD / ENA oligonucleotide) ■ VN-0102/JVC-001 (JP) (MMR vaccine) 	<ul style="list-style-type: none"> ■ Laninamivir (US/EU) (CS-8958 / Anti-influenza / out-licensing with Biota) 	<ul style="list-style-type: none"> ■ Mirogabalin (US/EU) (DS-5565 / Fibromyalgia / α2δ ligand) ■ Mirogabalin (JP/Asia) (DS-5565 / DPNP/ α2δ ligand) ■ Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand) ■ Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid μ-receptor regulator) <Injection> ■ CHS-0214 (JP) (Etanercept BS / Rheumatoid arthritis / TNFα inhibitor) ■ VN-0105 (JP) (DPT-IPV / Hib vaccine) ■ Laninamivir (JP) (CS-8958 / Anti-influenza / nebulizer) 	<ul style="list-style-type: none"> ■ Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid μ-receptor agonist)<Oral> ■ CL-108 (US) (Acute pain / Opioid μ-receptor agonist) ■ Intradermal Seasonal Influenza Vaccine (JP) (VN-100 / prefilled i.d. vaccine for seasonal flu) ■ VN-0107/MEDI3250 (JP) (Nasal spray flu vaccine) ■ Denosumab (JP) (AMG 162 / Rheumatoid arthritis / Anti-RANKL antibody)

Red: Major changes after the FY2016 Q2 financial announcement on October 31, 2016

Contact address regarding this material

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

TEL: +81-3-6225-1126

Email: DaiichiSankyoIR@daiichisankyo.co.jp